Compare Lufax Holding Ltd (LU) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lufax Holding Ltd vs Oscar Health Inc — how do they compare? Lufax Holding Ltd trades at $0.98 (market cap $982.89M), while Oscar Health Inc trades at $33.37 (market cap $10.22B). The key difference: Oscar Health Inc is far larger — about 10.4× Lufax Holding Ltd's market cap, and Oscar Health Inc is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lufax Holding Ltd for 13 Days and Oscar Health Inc for 15 Days on average.
| LU | OSCR | |
|---|---|---|
Market Cap | $982.89M | $10.22B |
Volume | 3,323,384 | 4,123,394 |
Sector | Financials | Health |
52-Week High | $3.78 | $33.81 |
52-Week Low | $0.95 | $10.85 |
Typical Hold Time | 13 Days | 15 Days |
Enterprise Value | $58.81B | $6.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lufax Holding Ltd (LU) trades at $0.9467, down 3.54% on the day, reflecting persistent bearish technical signals and fundamental challenges. The company reported a net loss of $2.10 billion in 2025 with revenue declining to $21.7 billion in 2026, though it maintains a low P/S of 0.25 and P/B of 0.07. Recent corporate actions include a 10:1 reverse stock split effective October 23, 2026, aimed at compliance, while analyst consensus remains predominantly buy-rated despite earnings misses.
The outlook hinges on Lufax's ability to stabilize revenue and narrow losses amid regulatory pressures in China's consumer lending sector. Deep value arguments based on tangible book value and Ping An backing present a speculative opportunity, but execution risks and sustained negative cash flows pose significant threats to near-term shareholder value.
OSCR trades at $33.10, up 0.58% with a bullish technical signal and strong institutional support. Recent earnings show volatility with Q1 and Q2 2026 beats but a Q4 2025 miss. Revenue grew from $11.7B in 2025 to $15.3B in 2026, with net income turning positive at $551M. Analyst consensus is mixed with 30.77% buy ratings and a $34.00 price target, slightly above current levels.
The outlook is cautiously optimistic with strong revenue growth and profitability improvements, though risks include medical cost pressures and competitive ACA market dynamics. Upside potential exists if margin expansion continues, but investors should monitor execution against guidance and healthcare sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
